Jin Shu

877 total citations
18 papers, 285 citations indexed

About

Jin Shu is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Jin Shu has authored 18 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Genetics and 4 papers in Oncology. Recurrent topics in Jin Shu's work include Chronic Lymphocytic Leukemia Research (5 papers), Endometrial and Cervical Cancer Treatments (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Jin Shu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Endometrial and Cervical Cancer Treatments (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Jin Shu collaborates with scholars based in China, United States and Australia. Jin Shu's co-authors include Timothy D. Owens, J. Michael Bradshaw, Philip A. Nunn, David Goldstein, Ken A. Brameld, Jacob LaStant, Claire L. Langrish, Yan Xing, Dane E. Karr and Michelle Francesco and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Jin Shu

18 papers receiving 279 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jin Shu China 9 111 89 86 64 52 18 285
Jacob LaStant United States 4 144 1.3× 51 0.6× 42 0.5× 50 0.8× 48 0.9× 4 236
Jennifer Postelnek United States 7 86 0.8× 79 0.9× 39 0.5× 48 0.8× 119 2.3× 12 269
Andy Boral United States 4 101 0.9× 181 2.0× 151 1.8× 72 1.1× 63 1.2× 4 287
Elizabeth Hall–Meyers United States 5 133 1.2× 97 1.1× 18 0.2× 159 2.5× 19 0.4× 6 313
Rita Andraos Switzerland 6 282 2.5× 120 1.3× 49 0.6× 98 1.5× 43 0.8× 7 411
Julie Switzky United States 8 128 1.2× 73 0.8× 80 0.9× 24 0.4× 47 0.9× 12 295
Su Young Kim United States 7 109 1.0× 62 0.7× 75 0.9× 30 0.5× 14 0.3× 12 237
Marie Laure Bonnet France 8 139 1.3× 115 1.3× 18 0.2× 196 3.1× 40 0.8× 20 327
Juan Luiz Coelho‐Silva Brazil 10 155 1.4× 54 0.6× 19 0.2× 78 1.2× 25 0.5× 35 264
Mitchell J. Geer United States 7 243 2.2× 35 0.4× 26 0.3× 97 1.5× 124 2.4× 9 388

Countries citing papers authored by Jin Shu

Since Specialization
Citations

This map shows the geographic impact of Jin Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin Shu more than expected).

Fields of papers citing papers by Jin Shu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin Shu. The network helps show where Jin Shu may publish in the future.

Co-authorship network of co-authors of Jin Shu

This figure shows the co-authorship network connecting the top 25 collaborators of Jin Shu. A scholar is included among the top collaborators of Jin Shu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin Shu. Jin Shu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Shu, Jin, et al.. (2023). Hyperuricemia is associated with metabolic syndrome: A cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES). Preventive Medicine Reports. 36. 102520–102520. 6 indexed citations
2.
Smith, Patrick F., Long Li, Fujun Li, et al.. (2023). Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants. Clinical and Translational Science. 16(7). 1210–1219. 11 indexed citations
3.
Xia, Lingfang, Qi Zhou, Yunong Gao, et al.. (2022). A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma. Nature Communications. 13(1). 7581–7581. 17 indexed citations
4.
Liu, Xin, Ting Fan, Jin Shu, et al.. (2022). Gadopentetate meglumine activates mast cells to cause IgE-independent allergic reactions both in vitro and in vivo. International Immunopharmacology. 106. 108602–108602. 2 indexed citations
5.
Shu, Jin, et al.. (2022). Licochalcone A inhibits IgE-mediated allergic reaction through PLC/ERK/STAT3 pathway. International Journal of Immunopathology and Pharmacology. 36. 1190355558–1190355558. 8 indexed citations
6.
Darpö, Börje, et al.. (2022). A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects. Clinical and Translational Science. 15(6). 1507–1518. 5 indexed citations
7.
Owens, Timothy D., Patrick F. Smith, Andrew Redfern, et al.. (2021). Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clinical and Translational Science. 15(2). 442–450. 36 indexed citations
8.
Langrish, Claire L., J. Michael Bradshaw, Michelle Francesco, et al.. (2021). Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease. The Journal of Immunology. 206(7). 1454–1468. 68 indexed citations
9.
Xing, Yan, Jyoti Wadhwa, Wei Chen, et al.. (2021). Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models. ImmunoHorizons. 5(7). 581–589. 12 indexed citations
10.
Wang, Haixia, Jin Shu, Dongling Zou, & Qi Zhou. (2021). Preliminary results of niraparib and brivanib dual therapy evaluation in recurrent, metastatic and persistent cervical cancer (CQGOG0101): An open-label, phase II clinical trial.. Journal of Clinical Oncology. 39(15_suppl). e17506–e17506. 1 indexed citations
11.
12.
Tang, Min, Yanli Hou, Xingyue Chen, et al.. (2014). All-trans-retinoic Acid Promotes Iodine Uptake Via Up-regulating the Sodium Iodide Symporter in Medullary Thyroid Cancer Stem Cells. Asian Pacific Journal of Cancer Prevention. 15(4). 1859–1862. 9 indexed citations
13.
Tang, Min, et al.. (2014). [Inhibitory effect of ¹³¹I-CD133mAb combined with cisplatin on liver cancer cells in vitro and in a tumor-bearing mouse model].. PubMed. 34(7). 934–8. 1 indexed citations
14.
Shu, Jin, et al.. (2011). Study of Migration of Different Petroleum Hydrocarbon Contaminated Components in Soil. Advanced materials research. 414. 198–202. 2 indexed citations
15.
Shu, Jin, et al.. (2011). Research on the Migration of Petroleum Hydrocarbon Contamination in the Soil in Different Leaching Amount. Advanced materials research. 414. 121–125. 1 indexed citations
16.
17.
Tao, Zezhang, et al.. (2006). [Analysis of the hearing of patients with obstructive sleep apnea-hypopnea syndrome].. PubMed. 20(1). 1–3. 3 indexed citations
18.
Shu, Jin, Ying Wang, Shujun Wang, et al.. (2005). [Identification of a novel HLA-A2-restrictive CTL epitope of an ovary cancer-associated antigen OVA66].. PubMed. 21(2). 233–6, 242. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacob LaStant Breakdown of academic impact, for papers by Jennifer Postelnek Breakdown of academic impact, for papers by Andy Boral Breakdown of academic impact, for papers by Elizabeth Hall–Meyers Breakdown of academic impact, for papers by Rita Andraos Breakdown of academic impact, for papers by Julie Switzky Breakdown of academic impact, for papers by Su Young Kim Breakdown of academic impact, for papers by Marie Laure Bonnet Breakdown of academic impact, for papers by Juan Luiz Coelho‐Silva Breakdown of academic impact, for papers by Mitchell J. Geer
Rankless by CCL
2026